NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Monday morning. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets dropped their price target on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Trading Down 2.2 %

NYSE:NBY opened at $0.59 on Monday. The firm has a market capitalization of $2.92 million, a PE ratio of -0.01 and a beta of 0.73. The stock has a 50 day moving average of $0.67 and a 200-day moving average of $1.47. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $11.45.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.